NCT04286451 (SLEEP-IN) is a NA clinical trial of Sleep Restriction in Sleep Disturbance, sponsored by Pennington Biomedical Research Center.

Who is sponsoring NCT04286451?

NCT04286451 is sponsored by Pennington Biomedical Research Center.

What drugs are being tested in NCT04286451?

Interventions in NCT04286451: Sleep Restriction, Habitual Sleep.

What condition does NCT04286451 study?

NCT04286451 studies Sleep Disturbance, Postmenopausal Symptoms, Insulin Sensitivity, Cardiovascular Risk Factor.

Is NCT04286451 still recruiting?

NCT04286451 is currently completed. Last updated 16 November 2022.

Last reviewed 2022-11-16 · How we verify

NCT04286451: SLEEP-IN

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Sleep Restriction on Adipose Tissue and Skeletal Muscle Insulin Sensitivity

Completed NA Last updated 16 November 2022

What this trial tests

NA trial testing Sleep Restriction in Sleep Disturbance in 14 participants. Completed in 13 April 2022.

Timeline

28 July 2020

Primary endpoint
13 April 2022

13 April 2022

Quick facts

Lead sponsor	Pennington Biomedical Research Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	diagnostic
Enrollment	14
Start date	28 July 2020
Primary completion	13 April 2022
Estimated completion	13 April 2022
Sites	1 location across United States

Drugs / interventions tested

Sleep Restriction
Habitual Sleep

Conditions studied

Sleep Disturbance — all drugs for Sleep Disturbance →
Postmenopausal Symptoms — all drugs for Postmenopausal Symptoms →
Insulin Sensitivity — all drugs for Insulin Sensitivity →
Cardiovascular Risk Factor — all drugs for Cardiovascular Risk Factor →

Sponsor

Pennington Biomedical Research Center — full company profile →

Who can join

Eligibility, female only, with Sleep Disturbance or Postmenopausal Symptoms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Inadequate sleep is an independent risk factor for metabolic abnormalities (such as obesity, insulin resistance, and hyperglycemia). Women report sleep disruption during the menopause transition (perimenopause) and into the postmenopausal years. Sleep disruption is one of the primary reasons why midlife women seek medical care, with up to 60% reporting significant sleep disturbances (e.g., trouble falling asleep, early morning waking, and hot flashes/night sweats). Despite the majority of women experiencing sleep disruption, no study has investigated the molecular mechanisms linking sleep disruption and the changes in metabolism that coincide with menopause.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Effect of sleep restriction on insulin sensitivity and energy metabolism in postmenopausal women: A randomized crossover trial.
Singh P, Beyl RA, Stephens JM, Noland RC, et al · · 2023 · cited 10× · PMID 36998155 · DOI 10.1002/oby.23739
Shortened sleep duration impairs adipose tissue adrenergic stimulation of lipolysis in postmenopausal women.
Singh P, Beyl RA, Stephens JM, Richard AJ, et al · · 2024 · cited 1× · PMID 39462901 · DOI 10.1002/oby.24162
Transcriptional remodeling of human skeletal muscle following sleep restriction in postmenopausal women.
Suryadevara HNSK, Hebert RC, Staszkiewicz J, Ravussin E, et al · · 2026 · PMID 41902670 · DOI 10.1152/physiolgenomics.00269.2025

Verify or expand the search:

Other trials of Sleep Restriction

Trials testing the same drug.

NCT05775627 — Sleep and Metabolism · NA · recruiting
NCT05956964 — NM Balance Regulation With ULLS and Loss of Sleep · NA · completed
NCT05393830 — The Effect of Sleep Loss on Emotion Regulation · NA · recruiting
NCT04955431 — Circadian Rhythm Disruption Effects on Smoke Inhalation · NA · completed
NCT05166590 — Sleep and Social Experiences Study 2 · NA · completed

Other recruiting trials for Sleep Disturbance

Currently open trials in the same condition.

NCT07503223 — Sleep Optimization With Acoustic Therapy · NA · recruiting
NCT07464626 — Virtual vs Physical Art Therapy for Anxiety, Psychological Well-being, and Sleep Quality in Colorectal Cancer Patients · NA · recruiting
NCT07386691 — Comparing Effect of Intradialytic Aerobic Exercise Versus Incentive Spirometer on Fatigue and Sleep Quality Among Hemodi · NA · active not recruiting
NCT07354776 — Effect of Isometric Neck Exercises on Cervicogenic Headache, Cortisol, and BDNF in Adolescents With Smartphone Addiction · NA · recruiting
NCT07119268 — SPARK Healthy Sleep · NA · recruiting

Other Pennington Biomedical Research Center trials

Trials by the same sponsor.

NCT07530718 — Body Composition Outcomes in MS Patients · not yet recruiting
NCT07095972 — Continuous Glucose Monitoring in Metabolic Surgery · NA · not yet recruiting
NCT07139821 — Dietary Iron Requirements · recruiting
NCT07318064 — Ultra-processed Food Consumption and Health Pilot Study · NA · not yet recruiting
NCT07305753 — CanCan Body Composition Study · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04286451 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pennington Biomedical Research Center
Last refreshed: 16 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04286451.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing